You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

buparlisib

Showing 1 - 15 of 15
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma Trial in United States (Buparlisib, Ibrutinib)

Completed
  • Lymphoma
  • +3 more
  • Basking Ridge, New Jersey
  • +5 more
Oct 7, 2022

Metastatic Transitional Cell Carcinoma of the Urothelium Trial in United States (Buparlisib)

Completed
Has Results
  • Metastatic Transitional Cell Carcinoma of the Urothelium
  • Buparlisib
  • Basking Ridge, New Jersey
  • +4 more
May 26, 2021

Renal Impairment Trial in Worldwide (Buparlisib)

Completed
  • Renal Impairment
  • Buparlisib
  • Sofia, Bulgaria
  • +3 more
Dec 6, 2020

Recurrent Glioblastoma Multiforme Trial in Worldwide (buparlisib, carboplatin, lomustine)

Completed
  • Recurrent Glioblastoma Multiforme
  • buparlisib
  • +3 more
  • Phoenix, Arizona
  • +13 more
Dec 6, 2020

Advanced or Metastatic Breast Cancer Trial in Spain, United States (LEE011, Buparlisib, Letrozole)

Completed
  • Advanced or Metastatic Breast Cancer
  • Los Angeles, California
  • +5 more
Dec 16, 2020

Chronic Lymphocytic Leukemia Trial in Canada (Buparlisib)

Completed
Has Results
  • Chronic Lymphocytic Leukemia
  • Buparlisib
  • Calgary, Alberta, Canada
  • +5 more
Apr 28, 2020

Carcinoma, Basal Cell, Recurrent Skin Cancer, Skin Tumors Trial in Stanford (Buparlisib, Sonidegib)

Terminated
Has Results
  • Carcinoma, Basal Cell
  • +3 more
  • Stanford, California
    Stanford University School of Medicine
Jan 10, 2019

Non-Small Cell Lunch Cancer Trial in Worldwide (Buparlisib, Buparlisib , Carboplatin)

Terminated
  • Non-Small Cell Lunch Cancer
  • Buparlisib
  • +3 more
  • Fayetteville, Arkansas
  • +6 more
Oct 9, 2018

Squamous NSCLC Trial in Worldwide (Buparlisib, Buparlisib matching , Docetaxel)

Terminated
  • Squamous Non-small Cell Lung Cancer
  • Buparlisib
  • +2 more
  • Fayetteville, Arkansas
  • +15 more
Aug 12, 2018

c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280,

Terminated
Has Results
  • c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280, BKM120, Buparlisib; Recurrent GBM
  • Boston, Massachusetts
  • +12 more
May 29, 2018

Head and Neck Squamous Cell Carcinoma Trial in Worldwide (Buparlisib, Buparlisib matching Placebo, Paclitaxel)

Terminated
Has Results
  • Head and Neck Squamous Cell Carcinoma
  • Buparlisib
  • +2 more
  • Fayetteville, Arkansas
  • +57 more
Jun 26, 2018

Breast Cancer Trial in Worldwide (alpelisib, buparlisib, Placebo)

Completed
Has Results
  • Breast Cancer
  • Birmingham, Alabama
  • +86 more
Aug 13, 2018

Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma Trial in Worldwide (Buparlisib)

Completed
Has Results
  • Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
  • Buparlisib
  • Boston, Massachusetts
  • +19 more
Aug 30, 2018

Malignant Melanoma, Metastases Trial in Dresden, Tuebingen (Buparlisib)

Unknown status
  • Malignant Melanoma
  • Metastases
  • Buparlisib
  • Dresden, Germany
  • +1 more
May 2, 2017

Adult Solid Tumor, Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA NSCLC Trial in Buffalo (Buparlisib, Cisplatin,

Withdrawn
  • Adult Solid Neoplasm
  • +4 more
  • Buparlisib
  • +5 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Aug 11, 2015